Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression Authors: Marco Krasselt Published: 2026 ABSTRACT AbstractPatients with inflammatory rheumatic diseases (IRDs) have a substantially increased risk of herpes zoster (HZ), driven by underlying immune dysregulation and immunosuppressive therapy, particularly high-dose glucocorticoids, biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors. The adjuvanted recombinant zoster vaccine (RZV) has shown high efficacy in preventing HZ in older adults and durable protection for at least 10 years. Emerging data in immunocompromised populations, including rheumatology cohorts, support clinically meaningful protection with an acceptable safety profile.Recent evidence includes randomised controlled trials demonstrating non-inferiority of RZV vs placebo for short-term flare risk in adults with IRDs on stable immunosuppression. Real-world cohort data also showed a marked reduction in HZ relapse after vaccination (approximately 95%), with very few flares and no serious vaccine-related events. In contrast, a pharmacovigilance analysis of 920 autoimmune patients identified an 8.5% flare incidence and a threefold increased reporting OR for post-RZV flares, particularly in systemic lupus erythematosus, underscoring the need for short-term monitoring and clear counselling rather than avoidance of vaccination.Updated recommendations from the European Alliance of Associations for Rheumatology, the American College of Rheumatology, the Advisory Committee on Immunisation Practices/Centers for Disease Control and Prevention and national bodies now support two doses of RZV for adults with IRD at increased HZ risk, including many receiving potent immunosuppression. This review summarises current evidence on the efficacy, effectiveness, durability and safety of RZV in IRD and interprets new data on vaccination-related autoimmune flares. It also proposes a practical vaccination strategy for rheumatology care and highlights key research gaps. WHAT IS ALREADY KNOWN ON THIS TOPIC Recombinant zoster vaccine (RZV) provides strong and durable protection against herpes zoster in the general population and is recommended for patients at increased risk because of immunosuppression. Recombinant zoster vaccine (RZV) provides strong and durable protection against herpes zoster in the general population and is recommended for patients at increased risk because of immunosuppression. WHAT THIS STUDY ADDS This review integrates randomized trial data, real-world cohort evidence and pharmacovigilance findings to show that RZV is effective in inflammatory rheumatic disease, with a marked reduction in herpes zoster recurrence in routine care. It also indicates that short-term post-vaccination flares are uncommon in trial and real-world settings, while pharmacovigilance data suggest a limited safety signal that supports short-term monitoring rather than vaccine avoidance. This review integrates randomized trial data, real-world cohort evidence and pharmacovigilance findings to show that RZV is effective in inflammatory rheumatic disease, with a marked reduction in herpes zoster recurrence in routine care. It also indicates that short-term post-vaccination flares are uncommon in trial and real-world settings, while pharmacovigilance data suggest a limited safety signal that supports short-term monitoring rather than vaccine avoidance. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The findings support broader and more systematic RZV implementation in inflammatory rheumatic disease, especially in patients receiving Janus kinase inhibitors, high-dose glucocorticoids or combination immunosuppression to overcome the low coverage. Table 1 provides practical timing guidance by immunosuppressive regimen and may help rheumatology teams improve counselling, reminder systems and responsibility assignment; future research should refine optimal timing, durability of protection and predictors of flares. The findings support broader and more systematic RZV implementation in inflammatory rheumatic disease, especially in patients receiving Janus kinase inhibitors, high-dose glucocorticoids or combination immunosuppression to overcome the low coverage. Table 1 provides practical timing guidance by immunosuppressive regimen and may help rheumatology teams improve counselling, reminder systems and responsibility assignment; future research should refine optimal timing, durability of protection and predictors of flares. Introduction Herpes zoster (HZ) and postherpetic neuralgia impose a significant burden on older adults and immunocompromised patients, with incidence rates of approximately 2–9 per 1000 person-years in the general population and even higher rates in immunocompromised people.1 Patients with inflammatory rheumatic diseases (IRD) roughly have a 1.5–2 fold higher risk of HZ compared with non-inflammatory controls, with further risk increments under glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs) and particularly Janus kinase (JAK) inhibitors.25 Historically, the live-attenuated zoster vaccine (ZVL) was contraindicated in most forms of clinically relevant immunosuppression, leaving a major preventive gap in rheumatology.1 6 ZVL could only be used in selected patients with IRD with stable low-level immunosuppression (typically before bDMARD therapy), but showed only moderate efficacy (~50%–70%) and limited real-world safety data in rheumatologic cohorts.1 Population-based data from Spain demonstrate that universal childhood varicella-zoster virus (VZV) vaccination substantially reduces severe varicella hospitalisations, with no concomitant increase in population-level HZ rates.7 Recombinant zoster vaccine (RZV) has closed this gap with substantially higher efficacy and a favourable safety profile even under ongoing immunosuppression. As a non-live, adjuvanted subunit vaccine that elicits robust humoral and CD4+ T-cell responses8 and is licensed for adults ≥50 years, and for adults ≥18 years at increased risk of HZ, including those with immunodeficiency or immunosuppression.912 While pivotal phase 3 trials excluded most immunosuppressed patients,8 13 subsequent studies in haematological malignancies, transplant recipients and people with HIV,8 14 together with emerging rheumatology-specific data,31518 now underpin strong recommendations for RZV use in IRD under immunosuppression.1 6 12 Recent observational and clinical data suggest that RZV is generally well tolerated in rheumatologic populations and show encouraging effectiveness signals; accordingly, RZV should be considered in most patients with IRDs at increased risk of HZ.7 19 20 A recent narrative review3 has summarised shingles vaccination strategies in immune-mediated inflammatory diseases, including the role of RZV. Accordingly, this review focuses on the efficacy/effectiveness, durability, safety and flare risk of RZV in immunosuppressed adults, particularly patients with IRD, while also addressing the practical implications for rheumatology care with regard to individual therapies. Burden of HZ in IRDs Multiple cohort studies and meta-analyses demonstrated that patients with IRD have a higher incidence of HZ compared with the general population, even after adjustment for age and comorbidities.14 In a large US claims analysis, patients with autoimmune and inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease had approximately a 1.5–2 fold greater risk of HZ.21 22 Some subgroups approached or exceeded the risk seen in immunocompetent adults ≥50 years. The risk for HZ is especially high in young patients with SLE.14 22 Type and intensity of immunosuppression are key modifiers of HZ risk: high-dose glucocorticoids, bDMARDs targeting T cells or B cells and JAK inhibitors consistently emerge as strong risk factors.5 14 In RA cohorts, JAK inhibitors substantially increase HZ incidence. This risk is further amplified by prior HZ, longer disease duration and (additional) glucocorticoid use.18 21 Beyond acute morbidity, HZ contributes to hospitalisation, postherpetic neuralgia, treatment interruptions and reduced quality of life, making vaccination a central preventive strategy in IRD.14 23 24 Vaccine characteristics and immunologic rationale of RZV RZV consists of the VZV glycoprotein E antigen combined with the AS01B adjuvant system. This liposomal formulation, containing monophosphoryl lipid A and QS-21, promotes strong innate activation and CD4+ T-cell responses (figure 1).8 Unlike ZVL, RZV is non-replicating and can be administered to immunocompromised individuals, provided general contraindications to vaccination are respected.8 14 Immune response to RZV and mechanistic sites of interference with its immunogenicity. Immune response to RZV. RZV (gE+AS01B) induces antigen uptake and AS01B-driven innate activation in antigen-presenting cells through early engagement of TLR4 and inflammasome pathways. This leads to activation of dendritic cells and monocytes, the emergence of interferon-related innate immune signatures and ultimately a dual adaptive response characterised by VZV gE-specific CD4+ Th1 memory responses and anti-VZV gE antibody production. Mechanistic sites of interference with RZV immunogenicity. Glucocorticoids (GC) suppress antigen uptake and innate activation in antigen-presenting cells. JAK inhibitors (JAKi) attenuate IFN- and cytokine-driven signalling at the APC level. TNF inhibitors (TNFi) dampen cytokine-mediated amplification of the response. Methotrexate (MTX) broadly suppresses lymphocyte expansion and proliferation. Abatacept (ABA) blocks CD28 co-stimulation and downstream T-cell help. Rituximab (RTX) depletes B cells and primarily impairs the humoral (anti-VZV gE antibody) response. Figure created with BioRender.com. APC, antigen-presenting cells; IFN, Interferon; JAK, Janus kinase; RZV, recombinant zoster vaccine; TLR4, toll-like receptor-4; VZV, varicella-zoster virus. In interpreting RZV immunogenicity in immunosuppressed patients, it is important to distinguish between humoral and cellular immune responses. Protection against VZV reactivation is largely driven by VZV-specific CD4+ T-cell immunity, whereas circulating antibody titres correlate only imperfectly with clinical protection (particularly in older adults and in those receiving immunosuppressive therapy).25 26 Studies in immunocompromised cohorts show that RZV induces robust VZV-specific CD4+ T-cell responses even when antibody titres are attenuated, and that cellular immunity may be partially preserved despite impaired humoral responses, suggesting that reliance on serological endpoints alone may underestimate vaccine-induced protection in IRD.8 25 27 Beyond AS01B-mediated Toll-like receptor-4 (TLR4) and inflammasome activation, RZV also elicits durable VZV-specific CD4+ T-cell responses.25 26 AS01-like adjuvants are further associated with interferon-related innate signatures that correlate with vaccine immunogenicity.28 29 This is particularly relevant for people with SLE, where type I interferon-driven immune activation shapes disease phenotype,30 and in patients treated with JAK inhibitors, in whom downstream interferon and cytokine signalling is pharmacologically modulated and may blunt both humoral and cellular responses to vaccination.31 Network meta-analyses and head-to-head comparisons in the general population demonstrate that RZV delivers significantly higher protection against HZ and postherpetic neuralgia than ZVL, although with increased local and systemic reactogenicity.14 16 An overall comparable serious adverse event profile is maintained, though.14 16 These immunologic and clinical characteristics make RZV particularly attractive for individuals with IRD, in whom durable CD4+ T-cell memory is critical and live vaccines are mostly contraindicated. Efficacy and long-term protection in the general adult population The phase 3 ZOE-5032 and ZOE-7033 trials established RZV as a highly efficacious vaccine in immunocompetent adults. In ZOE-50, vaccine efficacy against HZ was 97.2% in adults ≥50 years over a median 3.1-year follow-up. In contrast, ZOE-70 demonstrated 89.8% efficacy in adults ≥70 years over a median 3.7-year follow-up.32 33 A pooled post hoc analysis additionally showed that efficacy remained high (approximately 90%) in participants with at least one potential immune-mediated disease, although most were not on intensive immunosuppressive treatment.13 Long-term follow-up of these cohorts (ZOE-LTFU trial) provides critical data on durability.34 Overall efficacy against HZ remained 81.6% during years 5.6–9.6 postvaccination, with a cumulative efficacy of 89.0% from 1 month after dose two through a mean of 9.6 years.34 Anti-glycoprotein E antibody concentrations persisted at more than fivefold above baseline, gE-specific CD4+ T-cell frequencies at more than sixfold above baseline through year 10. No new safety signals were detected.34 These data indicate that in immunocompetent adults, two RZV doses provide at least a decade of clinically meaningful protection. Efficacy and safety in immunocompromised populations in general Based on several randomised trials and observational studies, the Advisory Committee on Immunisation Practices (ACIP) concluded that RZV confers substantial benefit in immunocompromised adults aged ≥19 years, including haematopoietic cell transplant recipients, patients with haematologic malignancies, solid organ transplant recipients and people living with HIV. Among these populations, vaccine efficacy against HZ ranged from about 68% in autologous haematopoietic cell transplant recipients to above 85%–90% in patients with haematologic malignancies and potential immune-mediated diseases, with similar relative efficacy across age groups.14 19 Humoral response rates of 65%–96% and cell-mediated response rates of 50%–93% were observed across six randomised trials in immunocompromised cohorts, contrasting minimal responses in placebo recipients,27 although absolute titres and T-cell frequencies were somewhat lower than in immunocompetent adults.8 25 Serious adverse events and immune-mediated disease events occurred at similar rates in both RZV and placebo groups.27 No clear signal for graft-versus-host disease or graft rejection emerged (CIs were wide though).14 These data underpin the approval and strong ACIP recommendation for RZV in immunocompromised adults.9 27 Available evidence in patients with IRDs The most robust rheumatology-specific RZV data currently come from a single-centre, double-blind, randomised, placebo-controlled, phase 4 non-inferiority trial conducted in Brazil. Aikawa et al enrolled 1192 adults with IRD (including RA, SLE, spondyloarthritis and others) on stable glucocorticoid and/or immunosuppressive (DMARD-)therapy. The patients were randomised 1:1 to two doses of RZV or placebo given 6 weeks apart, while an additional 393 healthy controls received open-label RZV.16 The primary endpoint was disease flare of the underlying IRD up to day 84 after the first dose. Non-inferiority was declared if the upper one-sided 95% CI for the between-group difference in flare rates was less than 5%. Flares occurred in 14% of RZV recipients vs 15% of placebo recipients (difference –1.2%, 95% CI –4.7% to 2.2%), meeting the non-inferiority criterion and indicating that RZV did not increase short-term flare risk.16 Reactogenicity (both local and systemic symptoms) was more frequent after RZV than placebo but was lower in patients with IRD than in healthy controls; serious adverse events were rare and similar across groups. Although the trial was not powered for clinical HZ endpoints or long-term outcomes, it provides compelling evidence for short-term safety and flare neutrality of RZV in people with IRD.16 Complementing these results, Valentini et al reported a single-centre, retrospective cohort study from Italy evaluating the effectiveness and safety of RZV in 114 adults with IRD compared with 65 general-care controls. The rheumatic cohort was heterogeneous, including RA, spondyloarthritis, connective tissue diseases and vasculitis; 33% received bDMARD monotherapy, 27% JAK inhibitors, 10% csDMARD monotherapy, 8% mycophenolate-mofetil and 14%–16% various combination regimens, while 28% received oral glucocorticoids only.15 The primary endpoint was HZ recurrence before vs after vaccination in patients with IRD, standardised per 100 patient-years. The incidence of HZ relapses declined from 9.29 episodes per 100 patient-years prevaccination to 0.45 episodes per 100 patient-years postvaccination (incidence rate ratio 0.0484, 95% CI 0.0024 to 0.965, p<0.001) corresponding to an approximately 95% relative reduction. Only one HZ recurrence occurred in the IRD cohort 14 weeks after the second RZV dose, and no relapses were recorded in the general-care group, despite a high baseline prevalence of prior HZ.15 Adverse events following immunisation were predominantly mild and transient (fever, injection-site reactions, myalgia, headache) occurring in 17.5% and 14.9% of patients with IRD after the first and second dose, respectively.15 These rates were similar to or even lower than among the controls. Only one patient (psoriatic arthritis, PsA) experienced a clinically meaningful IRD flare requiring glucocorticoid treatment. No serious vaccine-related or cardiovascular events were observed. Importantly, the safety and effectiveness profile did not differ regarding JAK inhibitor or bDMARD use, suggesting that RZV can be administered without interrupting advanced therapies in well-controlled patients.15 These findings in a broad spectrum of IRD diagnoses are complemented by recent US administrative data from adults with SLE, a population at particularly high baseline risk for HZ and severe disease activity. In a claims-based cohort study, 2284 patients with SLE who received a completed 2-dose RZV series were compared with 9020 matched unvaccinated controls in Medicare, and 1308 vaccinated with 5004 unvaccinated in commercially insured cohorts.35 HZ incidence was 5.9 and 19.8 events per 1000 person-years in vaccinated vs unvaccinated Medicare beneficiaries, corresponding to a vaccine effectiveness of 70% (95% CI 50% to 82%), and 7.4 vs 16.3 events per 1000 person-years in commercially insured patients, with an effectiveness of 54% (95% CI 18% to 74%). These results, together with the Italian IRD cohort, indicate that RZV provides substantial protection against HZ across diverse IRD subtypes, including highly immunosuppressed patients with SLE. While these studies are reassuring, they also have important methodological limitations that need to be acknowledged. The Italian cohort is single-centre, relatively small, and based on a pre–post comparison without a control group, which increases susceptibility to regression to the mean and residual confounding. Claims-based studies in SLE and other IRDs rely on administrative definitions of flares and HZ, which may misclassify outcomes and lack detailed clinical information, and the Brazilian phase 4 trial was not powered for long-term clinical endpoints. Taken together, the available data nevertheless strongly suggest that RZV is effective and well tolerated in IRD. Therapy-specific effects on vaccine immunogenicity Different immunosuppressive classes exert distinct effects on vaccine responses in general, which is highly relevant for interpreting RZV data in IRD. B-cell-depleting therapies (eg, rituximab) profoundly impair humoral responses and may blunt anti-gE antibody titres, with rituximab remaining one of the strongest negative predictors even in a recent phase 4 study, despite often preserved or only moderately reduced cellular immunity.163640 JAK inhibitors can attenuate both humoral and cellular responses through interference with interferon-driven and cytokine-driven signalling pathways.31 38 40 41 However, a prospective observational study found no significant impairment of RZV immunogenicity in patients with RA on JAK inhibitors, with anti-VZV IgG titres rising comparably to healthy controls without treatment interruption.42 More recent randomised substudy data further indicate a moderate effect under upadacitinib, with satisfactory humoral responses in approximately 88% of RA patients on background methotrexate.43 Both glucocorticoids and methotrexate are able to suppress vaccine immunogenicity, with a clearer dose-related or exposure-related effect for methotrexate and stronger suppression primarily at higher glucocorticoid doses, whereas low-dose glucocorticoids (≤5–7.5 mg prednisone equivalent) appear to have minimal impact.37 38 40 43 44 In contrast, anti-TNF therapies and most other cytokine inhibitors are generally associated with less pronounced reductions in vaccine responses than B-cell depletion or JAK inhibition.15 36 38 40 45 46 Abatacept though exerts an intermediate to pronounced attenuating effect via T cell co-stimulation blockade; a recent pilot randomised controlled trial (RCT) demonstrated reduced humoral (42%) and especially cellular RZV responses (10%), although the vaccine was safe.17 36 40 47 These drug class-specific differences should be considered when extrapolating from immunocompetent populations and when counselling patients about expected vaccine responsiveness under different treatment regimens. Figure 1 summarises the immune response to RZV and the principal therapy-specific sites of interference. Other rheumatology-relevant data Several studies not confined to rheumatology provide additional reassurance for RZV in patients with immune-mediated diseases.3 6 8 14 A pooled post hoc analysis of the pivotal ZOE-50/70 trials found that participants with pre-existing potential immune-mediated diseases had RZV efficacy and serious adverse event profiles comparable to the overall trial population.13 Systematic reviews of RZV effectiveness and safety in both immunocompetent and immunocompromised subjects confirm high efficacy against HZ and acceptable safety, though with increased reactogenicity, across a wide range of settings.8 14 Prospective observational work has demonstrated good immunogenicity and an acceptable safety profile of RZV in patients with RA treated with bDMARDs or JAK inhibitors, with seroconversion rates approaching those of immunocompetent adults (except for rituximab and abatacept).15 17 18 21 Furthermore, flare rates were low, though these data are still limited and mostly come from small cohorts.16 17 21 Collectively, these data reinforce the notion from rheumatology-specific cohorts that RZV is effective and well tolerated across IRD diagnoses and different immunosuppressive therapies.61517 Autoimmune disease flares and immune-mediated adverse events Despite the reassuring efficacy and safety data, autoimmune flares after RZV remain a concern in rheumatology. In practice, many clinicians therefore ask whether the benefits of vaccination truly outweigh the risk of a flare, particularly in SLE. Liu and colleagues performed a VAERS (Vaccine Adverse Event Reporting System)-based pharmacovigilance analysis of RZV-associated flares in adults with RA, SLE, multiple sclerosis (MS), psoriasis and inflammatory bowel disease between 2017 and the third quarter of 2024.48 Among 920 individuals with autoimmune diseases, 78 reported flares, corresponding to an 8.5% flare incidence and a threefold increased reporting OR (ROR 3.00, 95% CI 2.40 to 3.75) compared with the overall VAERS background. Disease-specific RORs were highest for SLE (ROR 7.50), MS (5.61) and RA (5.03), with lower but still statistically significant signals for psoriasis and IBD.48 Most flares (59%) occurred within 3 days of vaccination, indicating an early-onset pattern consistent with strong innate immune activation. No associations with age, sex or dose number were seen.48 By contrast, large real-world cohort studies with clinical endpoints are more reassuring.18 21 Leung et al analysed administrative claims from more than 45 000 adults ≥50 years with immune-mediated inflammatory diseases in the USA and found no statistically significant increase in presumed flares within 30 days after either RZV dose.21 Similarly, in a matched cohort and self-controlled case-series study of 1926 vaccinated and 5746 unvaccinated adults ≥50 years with RA, Rayens et al observed no increased risk of RA flares within 30 days following RZV (rate ratio 1.02, 95% CI 0.75 to 1.37). The study also showed approximately 60% vaccine effectiveness against HZ and nearly 90% effectiveness against postherpetic neuralgia.18 Smaller rheumatology series, including the Italian single-centre cohort by Valentini et al, also report flare rates in the range of 5%–16%, typically mild to moderate and manageable with short glucocorticoid courses.15 48 SLE-specific data highlight that RZV can be administered without incrementing the risk of severe disease activity. In a large US claims-based cohort of adult patients with SLE, the HR for severe SLE flares within 90 days after RZV was comparable between vaccinated and unvaccinated individuals.35 In a current multicentre, double-blind, RCT in patients with RA receiving abatacept, RZV did not increase flare risk versus placebo. The proportion of patients with RA flare was similar in both groups (68% vs 64%), with no additional safety signal.17 Mechanistically, the AS01B adjuvant may trigger short-term immune perturbations through transient CD4+ T-cell activation in predisposed individuals.48 However, rates of immune-mediated disease onset or exacerbation in RZV vs placebo arms of randomised trials in immunocompromised populations were generally similar.9 48 ACIP judged the overall risk of serious immune-mediated events to be small compared with the benefits of HZ prevention.9 Pharmacovigilance data48 are useful for signal detection but are inherently subject to reporting bias, whereas observational cohorts15 18 21 provide more reliable incidence estimates in routine care. RCT data,16 17 which are less susceptible to confounding, do not suggest an increased short-term flare risk. Overall, the evidence does not support a clinically meaningful increase in flare risk after RZV, although mild and early flares may occur in a minority of susceptible patients. In routine practice, rheumatologists balance this small flare risk against the clear benefit of HZ prevention, particularly in patients with SLE or those receiving JAKi. Rheumatology guideline recommendations The 2019 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for vaccination in adult patients with IRD stressed that HZ vaccination should be considered in high-risk patients, historically with live attenuated vaccine administered at least 4 weeks before starting bDMARDs or JAK inhibitors and avoided during established biologic therapy. With the licensure of RZV, EULAR now implicitly favours the RZV for patients with IRD at increased risk, even if the formal wording still reflects the former ZVL era.1 2 National policies in Europe may vary, but many countries offer RZV to adults ≥50 or ≥60 years and to younger high-risk individuals, and recent reviews emphasise its preferential role for patients with IRD over ZVL.8 The Standing Committee on Vaccination (STIKO) in Germany, for example, not only recommends RZV as a routine vaccination for all adults aged ≥60 years but also as an indication vaccination for adults aged ≥18 years with an increased risk of HZ (congenital or acquired immunodeficiency, severe chronic disease, including IRD).11 12 The latter recommendation was introduced only shortly at the end of 2025. American College of Rheumatology (ACR) guideline on vaccinations in patients with IRD from 2022 goes further, strongly recommending RZV for adults receiving immunosuppressive treatment (including JAK inhibitors, B-cell depleting agents and conventional DMARDs). RZV should ideally be administered before initiating B-cell-depleting therapy whenever feasible.6 Also published in 2022, ACIP’s recommendations explicitly endorse two RZV doses for adults aged ≥19 years who are or will be immunodeficient or immunosuppressed due to disease or therapy, with a standard 2–6-month dosing interval. In situations where rapid protection is needed, this interval may be shortened to 1–2 months.9 HZ vaccination coverage in IRD Despite these clear guideline recommendations, HZ vaccination coverage among patients with IRDs remains low. In a German single-centre cohort of 222 patients with IRDs, only 13.1% ever received a zoster vaccine, the lowest coverage among the three vaccines assessed and markedly below influenza (68.5%) and pneumococcal vaccination (34.7%).2 HZ vaccination was significantly more frequent in patients ≥60 years, reflecting age-based national STIKO recommendations at that time.2 In a nationwide Israeli health plan study (more than 14 000 patients with RA, PsA and SLE), real-world RZV coverage was similarly poor at 3.6%, with younger adults and those with fewer comorbidities showing the lowest uptake despite an elevated risk.49 US claims data indicate that, shortly after RZV licensure, only 14.8% of commercially insured and 43.2% of Medicare beneficiaries aged ≥50 years with immune-mediated inflammatory diseases had received at least one RZV dose in 2018–2019, although series completion rates among initiators were high (76%–85%).21 More recent mixed-methods work suggests that, even after ACIP expanded recommendations to immunosuppressed adults ≥19 years, RZV uptake among US patients with IRDs remains suboptimal: rheumatologists citing time constraints, competing priorities and uncertainty about responsibility for vaccination as key barriers.50 51 Collectively, these data highlight a persistent implementation gap in HZ vaccination that is particularly pronounced in younger patients with IRD, underscoring the actual need for systematic vaccination counselling and reminder systems in rheumatology practice. Beyond individual counselling, improving vaccine uptake in IRD will likely require system-level interventions. Electronic health record-based reminders or best-practice alerts can reduce missed opportunities by identifying eligible patients and have already improved pneumococcal and other vaccine coverage in IRD settings before. Shared responsibility between rheumatology and primary care, supported by clearly defined vaccination pathways, may help ensure that patients are neither overlooked in specialist clinics nor assumed to be fully addressed elsewhere. Patient education should complement these measures through written material and portal-based reminders, which can improve readiness to vaccinate and support adherence to scheduled doses. Practical vaccination strategy for patients with IRD RZV implementation in rheumatologic practice should be grounded in individual HZ risk stratification.1 This not only includes current and planned immunosuppression, but also the judgement of disease activity.1 8 Patients at particularly high risk are those aged ≥50 years, those of any age on JAK inhibitors or high-dose glucocorticoids, individuals with prior HZ, and those with multiple comorbidities or concomitant malignancy.15 52 For such patients, most guidelines now support prioritising RZV even at younger ages, often from 18 years onward, if potent immunosuppression is in place or imminent.1 6 9 12 Where feasible, vaccination should be completed before starting B-cell depleting therapies (eg, rituximab, CAR T-cell therapy) or immunosuppressive combination regimens.1 Ideally, at least a 2-week interval should be allowed between the second RZV dose and initiation of treatment.6 For patients already receiving immunosuppressants, ACR and ACIP support vaccination without routine interruption of therapy. For seasonal influenza vaccination, randomised trials by Park et al53 54 indicate that a 1–2-week methotrexate hold around vaccination may enhance immunogenicity without compromising disease control. For pneumococcal vaccination, the VACIMRA trial44 similarly supports timing PCV13 before initiation of methotrexate to optimise antibody responses. More broadly, these timing principles align with the wider IRD vaccine literature, which shows heterogeneous vaccine responses under immunosuppression across influenza, pneumococcal and SARS-CoV-2 vaccines, with particularly impaired humoral responses under methotrexate, abatacept and rituximab but relative preservation of cellular immunity in many patients. In selected individuals, scheduling doses of RZV and other non-live vaccines midway between rituximab infusions or considering transient methotrexate or abatacept pauses may therefore optimise immunological responses.16 17 44 5355 Key timing principles are summarised in table 1. Table 1Suggested timing of RZV in adults with IRD according to immunosuppressive therapyDrugHZ riskRZV recommendationSuggested timingTreatment hold?EvidencecsDMARDs (MTX, leflunomide, sulfasalazine)ModerateStrongly recommended in all patients ≥50 years; consider from 18 years if additional risk factorsAny time; ideally during stable diseaseIndividually consider 1–2 week MTX-hold after each dose in stable RAACR guideline; MTX-hold extrapolated from influenza and pneumococcal vaccination data in MTX-treated patients6 44 53 54; (moderate certainty for MTX-hold)Cytokine inhibitors (eg, TNF, IL-6, IL-17 and IL-23 inhibitors, T-cell co-stimulation inhibitorModerateStrongly recommendedAny time during maintenance therapyNo routine holdNo signals for serious immune-mediated events in RZV trials and IRD cohorts; ACR/ACIP allow vaccination on therapy1 6 8 9 56; (moderate certainty)AbataceptModerateStrongly recommendedPreferably vaccinate before treatmentIndividually consider 1 week Abatacept-hold before and after each dose in stable RAACR guideline, DGRh recommendations6 17 40 55 57; (low certainty for hold)JAK inhibitorsHighPrioritise RZV irrespective of age in long-term usersPreferably before or early after JAKi start; if already on JAKi, vaccinate without interruptionNo routine hold; consider individualised approach in unstable diseaseMarkedly increased HZ risk under JAKi; no evidence that short JAKi holds improve immunogenicity4 6 15 52; (low-moderate certainty for timing or hold)B-cell-depleting therapies (eg, rituximab, obinutuzumab)HighStrongly recommended before or between cyclesIdeally complete 2 doses ≥2 weeks before first infusion; if already on treatment, vaccinate mid-cycle (≥4–6 months after last and ≥4 weeks before next infusion)No evidence-based hold; adjust timing rather than stopping the therapyB-cell depletion blunts humoral responses; transplant and RA data support mid-cycle vaccination strategy1 8 15 36; (moderate certainty, timing adjustments rather than holding)High-dose glucocorticoids (≥10–20 mg prednisolone equivalent)HighStrongly recommended regardless of ageIf possible, vaccinate when dose is being taperedNo routine hold (risk of disease flare outweighs potential benefit)High GC-associated HZ risk; RZV is safe under GCs4 6 8 15;(low-moderate certainty)Combination immunosuppression (eg, csDMARD+bDMARD+GC)HighStrongly recommended; consider prioritising even in 18–49 yearsPreferably before escalation to combination therapy or during most stable phaseNo routine hold; individualised decisionsHighest HZ risk in combination regimens; benefit–risk ratio most favourable6 15 58; (low certainty, evidence largely extrapolated from heterogeneous cohorts and the incremental effects of combined therapies)ACIP, Advisory Committee on Immunisation Practices; ACR, American College of Rheumatology; bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DGRh, Deutsche Gesellschaft für Rheumatologie und Klinische Immunologie; GC, glucocorticoids; HZ, herpes zoster; IL, interleukin; IRD, inflammatory rheumatic disease; JAKi, Janus kinase inhibitor; MTX, methotrexate; RA, rheumatoid arthritis; RZV, recombinant zoster vaccine; TNF, tumour necrosis factor. Suggested timing of RZV in adults with IRD according to immunosuppressive therapy ACIP, Advisory Committee on Immunisation Practices; ACR, American College of Rheumatology; bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DGRh, Deutsche Gesellschaft für Rheumatologie und Klinische Immunologie; GC, glucocorticoids; HZ, herpes zoster; IL, interleukin; IRD, inflammatory rheumatic disease; JAKi, Janus kinase inhibitor; MTX, methotrexate; RA, rheumatoid arthritis; RZV, recombinant zoster vaccine; TNF, tumour necrosis factor. In all cases, vaccination is ideally performed during low or moderate disease activity.1 6 Clear counselling should be provided regarding common local and systemic reactions in the first 72 hours after vaccination, as well as the small risk of autoimmune flares, particularly in patients with SLE.1 8 21 48 Close short-term monitoring—either by telemedicine or brief in-person consultation—for 3–7 days after each dose may be prudent in patients with highly active disease, prior severe flares or complex combination immunosuppression. Robust documentation and, where feasible, contribution to pharmacovigilance or registry initiatives will be important to refine flare risk estimates and to characterise predictors of adverse outcomes over time. Knowledge gaps and research priorities Despite major progress, several important questions remain unanswered for patients with IRD. First, the durability of protection and optimal timing for potential booster in heavily immunosuppressed people are unknown. While immunocompetent adults retain high efficacy for at least 10 years, it is plausible that protection wanes faster under chronic immunosuppression. In addition, future studies should identify biomarkers that predict vaccine response, including baseline humoral status, B-cell reconstitution and treatment-specific immune profiles. Immune phenotyping approaches, particularly interferon signatures and other innate immune markers, may help explain interindividual heterogeneity in vaccine responsiveness and flare risk. Second, the impact of specific biologic and targeted synthetic DMARDs on RZV immunogenicity (particularly B-cell depleting agents, JAK inhibitors and combination regimens) needs more prospective, disease-specific studies with standardised humoral and cellular endpoints. These data could inform personalised vaccination strategies that integrate disease activity, immunosuppressive regimen and optimal vaccine timing. Third, while the discussed Brazilian RCT provides strong short-term safety data, longer-term follow-up of HZ incidence, sustained disease activity outcomes and flare patterns, as well as in other large pragmatic trials or ‘target trial emulations’ using registry and claims data, will be essential. Fourth, important vaccination implementation gaps remain. Data on RZV uptake, patient and physician barriers, and the real-world impact of structured vaccination campaigns in frail and immunosuppressed populations are still limited.18 51 Additional real-world studies are needed to define how implementation strategies can be most effectively integrated into routine rheumatology care. Fifth, better characterisation of humoral vs cellular correlates of protection is needed, since antibody titres alone do not fully capture clinically meaningful immunity under immunosuppression. Sixth, the mechanistic basis of autoimmune flares after RZV requires translational studies integrating cytokine profiles, innate immune signatures and antigen-specific T-cell responses. Finally, cost-effectiveness analyses tailored to IRD, which incorporate the high cost of JAK inhibitor-associated HZ, hospitalisations and postherpetic neuralgia, could help refine age and risk thresholds for recommending RZV in younger adults. Conclusions Current evidence supports RZV as a highly efficacious vaccine against HZ in immunocompetent adults. Protection persists for at least a decade at an acceptable long-term safety profile. In immunocompromised populations, including haematological malignancies, transplant recipients and patients with immune-mediated diseases such as IRD, RZV demonstrates substantial efficacy, robust immunogenicity and no major safety concerns. Its use in immunodeficient or immunosuppressed adults is therefore recommended by multiple national and international authorities. Within rheumatology, randomised trials and real-world cohorts indicate that RZV does not increase short-term flare risk compared with placebo and is well tolerated across different IRDs, including under JAK inhibitors and bDMARDs. Data also show substantial protection against HZ recurrences. Large real-world studies in IRDs similarly show no increased 30-day flare risk, while confirming substantial effectiveness against HZ and postherpetic neuralgia. In contrast, pharmacovigilance analyses reveal a modest flare signal, particularly in SLE, supporting informed consent and short-term monitoring rather than vaccine avoidance. Overall, current evidence strongly favours RZV vaccination in most patients with IRD receiving immunosuppressive therapy, with benefits outweighing the small risk of short-term flare. Vaccination timing should be individualised, depending on the intensity and type of immunosuppression and the level of disease activity. Future research should focus on long-term outcomes, immunogenicity and predictors of autoimmune flares after RZV in IRD. Longer-term follow-up and better biomarker data are needed to refine risk-based decision-making in daily practice.